| Public | NASDAQ:ANTH |
| Date | 3/10 |
| Website | anthera.com |
| Category | BioTech |
| Phone | 510-856-5600 |
| Employees | |
| Founded | 2004 |
| TOTAL | $31.5M |
| VENTURE FUNDING TOTAL | $31.5M |
| Venture Round, 9/10 OrbiMed Advisors Caxton Associates | $31.5M |
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
